Literature DB >> 15045495

In vivo 1H magnetic resonance spectroscopy of rat brain after valproate administration.

J Leib1, J Braun, A Schilling, C Klingner, S Seyfert, W Vollmann, E Gedat, J Bernarding.   

Abstract

Previous studies have shown that valproate is detectable in vitro by 1H magnetic resonance spectroscopy (MRS) at 1.5 T, whereas in patients on valproate monotherapy, no significant dose-dependent valproate signal could be seen. To investigate whether an increased signal-to-noise ratio as provided by higher valproate doses and increased magnetic field strength would enable detection of valproate in vivo, six Wistar rats were examined using volume-selective 1H MRS at 2.34 T. The spectra were analyzed by fitting a linear superposition of the basis spectra of valproate, brain metabolites, and simulated lipid signals. The analysis revealed no significant signal contributions after valproate administration of up to 330 mg/kg body weight. To analyze how underlying mechanisms, such as potential drug interactions with macromolecules, may affect the valproate signal, additional in vitro spectra of valproate were measured before and after adding albumin. The spectra exhibited a strong decrease of the valproate signal with increasing albumin concentration. The results support the hypothesis that in vivo valproate is bound to a high degree to macromolecules and will therefore not be detectable by 1H MRS. Copyright 2004 Springer-Verlag

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15045495     DOI: 10.1007/s00234-004-1182-6

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  20 in total

1.  Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain.

Authors:  J Pfeuffer; I Tkác; S W Provencher; R Gruetter
Journal:  J Magn Reson       Date:  1999-11       Impact factor: 2.229

2.  Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures.

Authors:  O A Petroff; D L Rothman; K L Behar; F Hyder; R H Mattson
Journal:  Seizure       Date:  1999-04       Impact factor: 3.184

Review 3.  Possible mechanisms of valproate in migraine prophylaxis.

Authors:  F M Cutrer; V Limmroth; M A Moskowitz
Journal:  Cephalalgia       Date:  1997-04       Impact factor: 6.292

4.  Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission.

Authors:  M Maes; J Calabrese; K Jayathilake; H Y Meltzer
Journal:  Psychiatry Res       Date:  1997-07-04       Impact factor: 3.222

5.  Volume-selective proton MR spectroscopy for in-vitro quantification of anticonvulsants.

Authors:  J Braun; S Seyfert; J Bernarding; A Schilling; P Marx; T Tolxdorff
Journal:  Neuroradiology       Date:  2001-03       Impact factor: 2.804

6.  Effect of inhibitors of GABA transaminase on the synthesis, binding, uptake, and metabolism of GABA.

Authors:  W Löscher
Journal:  J Neurochem       Date:  1980-06       Impact factor: 5.372

7.  Distribution of drugs over whole blood: I. The transport function of whole blood for valproate.

Authors:  O Driessen; L Treuren; J W Meijer
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

8.  Postmortem serum protein binding and brain concentrations of antiepileptic drugs in autoptic specimens from 45 epileptic patients.

Authors:  B Rambeck; R Schnabel; T May; U Jürgens; R Villagrán
Journal:  Ther Drug Monit       Date:  1990-11       Impact factor: 3.681

9.  Low and variable presence of valproic acid in human brain.

Authors:  D D Shen; G A Ojemann; R L Rapport; R L Dills; P N Friel; R H Levy
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

10.  GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate.

Authors:  N Motohashi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1992-07       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.